237 related articles for article (PubMed ID: 21644373)
1. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
Hinneburg I
Med Monatsschr Pharm; 2011 May; 34(5):154-8. PubMed ID: 21644373
[TBL] [Abstract][Full Text] [Related]
2. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Billman GE
Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
[TBL] [Abstract][Full Text] [Related]
3. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
Vizzardi E; Salghetti F; Bonadei I; Gelsomino S; Lorusso R; D'Aloia A; Curnis A
Cardiovasc Ther; 2013 Oct; 31(5):e55-62. PubMed ID: 23398692
[TBL] [Abstract][Full Text] [Related]
4. Vernakalant in the management of atrial fibrillation.
Cheng JW
Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
[TBL] [Abstract][Full Text] [Related]
5. Vernakalant: A novel agent for the termination of atrial fibrillation.
Finnin M
Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
7. Vernakalant hydrochloride for the treatment of atrial fibrillation.
Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
[TBL] [Abstract][Full Text] [Related]
8. Vernakalant. Too dangerous in atrial fibrillation.
Prescrire Int; 2012 May; 21(127):119-22. PubMed ID: 22827000
[TBL] [Abstract][Full Text] [Related]
9. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
[TBL] [Abstract][Full Text] [Related]
11. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
Hirt MN; Eschenhagen T
Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
[TBL] [Abstract][Full Text] [Related]
12. 1:1 atrial flutter after vernakalant administration for atrial fibrillation cardioversion.
de Riva-Silva M; Montero-Cabezas JM; Salgado-Aranda R; López-Gil M; Fontenla-Cerezuela A; Arribas-Ynsaurriaga F
Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1062-4. PubMed ID: 22727797
[No Abstract] [Full Text] [Related]
13. Vernakalant for the conversion of atrial fibrillation: the new kid on the block?
Conde D; Baranchuk A
Ann Noninvasive Electrocardiol; 2014 Jul; 19(4):299-302. PubMed ID: 24738652
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
Mao ZL; Townsend RW; Gao Y; Wheeler JJ; Kastrissios H; Keirns J
J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
[TBL] [Abstract][Full Text] [Related]
15. Vernakalant: pharmacology electrophysiology, safety and efficacy.
Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
Drugs Today (Barc); 2008 May; 44(5):325-9. PubMed ID: 18548135
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.
Blomström-Lundqvist C; Blomström P
Expert Opin Drug Saf; 2012 Jul; 11(4):671-9. PubMed ID: 22632377
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
[TBL] [Abstract][Full Text] [Related]
18. The pharmaceutical pipeline for atrial fibrillation.
Santangeli P; Di Biase L; Pelargonio G; Burkhardt JD; Natale A
Ann Med; 2011 Feb; 43(1):13-32. PubMed ID: 21166558
[TBL] [Abstract][Full Text] [Related]
19. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
Conde D
Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
[TBL] [Abstract][Full Text] [Related]
20. Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.
Cialdella P; Pedicino D; Santangeli P
Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):1-8. PubMed ID: 21235460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
